Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity
- 1 December 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 70 (18), 2409-2438
- https://doi.org/10.2165/11585260-000000000-00000
Abstract
Both the discovery of the endocannabinoid system (ECS) and its role in the control of pain and habituation to stress, as well as the significant analgesic and antihyperalgesic effects in animal studies, suggest the usefulness of cannabinoids in pain conditions. However, in human experimental or clinical trials, no convincing reduction of acute pain, which may be caused by a pronociceptive, ECS-triggered mechanism on the level of the spinal cord, has been demonstrated. In contrast, in chronic pain and (painful) spasticity, an increasing number of randomized, double-blind, placebo-controlled studies have shown the efficacy of cannabinoids, which is combined with a narrow therapeutic index. Patients with unsatisfactory response to other methods of pain therapy and who were characterized by failed stress adaptation particularly benefited from treatment with cannabinoids. None of the attempts to overcome the disadvantage of the narrow therapeutic index, either by changing the route of application or by formulating balanced cannabinoid preparations, have resulted in a major breakthrough. Therefore, different methods of administration and other types of cannabinoids, such as endocannabinoid modulators, should be tested in future trials.Keywords
This publication has 161 references indexed in Scilit:
- Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the BedsideNeurotherapeutics, 2009
- Modulation of the anti‐nociceptive effects of 2‐arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain modelBritish Journal of Pharmacology, 2008
- Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical TrialNeuropsychopharmacology, 2008
- Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory painBritish Journal of Pharmacology, 2007
- Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptorsNature Neuroscience, 2007
- Inhibitors of monoacylglycerol lipase as novel analgesicsBritish Journal of Pharmacology, 2007
- Effects of Marijuana Smoking on Pulmonary Function and Respiratory ComplicationsArchives of Internal Medicine, 2007
- Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysisBritish Journal of Pharmacology, 2007
- AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic painBritish Journal of Pharmacology, 2006
- Cannabis and endocannabinoid modulators: Therapeutic promises and challengesClinical Neuroscience Research, 2005